



**PROSMAN** <sup>TM</sup>

Supports Healthy Prostate

CLINICALLY EVALUATED  
&  
PATENTED INGREDIENT



[www.prosman.in](http://www.prosman.in)

## **INTRODUCTION**

BPH or Benign Prostate Hyperplasia is a non-malignant enlargement of the prostate. Or simply put, it is a condition in which the prostate enlarges. BPH symptoms can be most common in older men.

BPH is considered a normal condition of male ageing, and found in more than 10% of men in their 30s, 20% of men in their 40s, reaches 50% to 60% of men in their 60s, and is 80% to 90% of men in their 70s and 80s.

BPH represents a substantial challenge to public health.

## **HEALTHY AGEING**

PROSMAN™ is an innovative product for management of BPH. It is derived from Prunus species that has anti-inflammatory effects on the prostate. Also, PROSMAN comprises of active constituents beta-sitosterol & decoys I ferulate.

Prosman is a well-researched and well-documented product.

## **ROLE OF PROSMAN**

Prosman is an innovative product derived from a single herb. It comprises of active ingredient that have anti-inflammatory effects by inhibiting production of pro-inflammatory prostaglandins in the prostate. It also inhibits the production of androgenic steroid hormones such as testosterone and dihydrotestosterone (DHT) which stimulate the growth and development of the prostate through hyperplasia (proliferation of prostatic cells), one of the main causes of BPH.

After thorough research, we developed an innovative process for the extraction of Prosman, duly patented by USA, Europe, Japan, China and Korean patents.

Prosman is sourced from renewable prunes of Prunus species rather than the endangered Prunus Africana trees.

Men's health industry is well-aware that pygeum supplies are dwindling. As a protected species, it could be another 30-50 years before current cultivation efforts in Africa restore the supply. Thankfully, we have a pygeum alternative with 98.5 percent profile similarity and statistically comparable effects.

## **CLINICAL STUDY**

An open-labelled, single-armed & non-randomized clinical study was carried out on 140 Patients of BPH to test the efficacy and safety of PROSMAN.

**Primary objective:** Efficacy evaluation of Prunus species extract in patients with benign prostate hyperplasia (BPH)

### **EFFICACY CONCLUSIONS**

On completion of the study, following efficacy conclusions were made:

- ♀ A significant decrease in IPSS score was observed after 4 weeks and on completion of treatment. All the patients reported decrease in IPPS score.
- ♀ 94% of the patients showed decrease in the prostate volume. A total of 29.46% decrease in the prostate volume was observed. The significant decrease was observed even after four weeks of the treatment.
- ♀ The decrease in serum PSA levels was 56%, which was statistically significant. 76% of the patients showed decrease in serum PSA levels on completion of the treatment.
- ♀ A highly significant increase in the serum testosterone levels was observed. The increase was 17.28%. The mean serum testosterone levels were within normal range on completion of treatment.
- ♀ Sonographic evaluation of the patients showed marked improvement in the percentage of patients getting normalized on completion of the treatment. At baseline, 93% of the patients had mildly enlarged prostate, whereas on completion of the treatment 43% of the patients showed normal prostate.

### **SAFETY CONCLUSION**

On completion of the study, following safety conclusions were made:

- ♀ No significant change in the liver function tests (serum glutamic-oxaloacetic transaminase, serum glutamic-pyruvic transaminase and alkaline phosphates activities) was observed.
- ♀ No significant change in the serum urea levels and creatinine levels was observed.
- ♀ No significant change in the hematological parameters was observed on completion of the treatment.

## **SALIENT FEATURES**

PROSMAN™ is a powerful antioxidant derived from Prunus species bark.

- ♀ Novel antioxidant matrix supports prostate health
- ♀ Botanical profile 98.5 percent similar to pygeum
- ♀ Demonstrate broad spectrum safety
- ♀ Acute oral toxicity established at 5,000mg/kg body weight
- ♀ Ames' bacterial reverse mutation assay, conducted under GLP, confirmed its non-mutagenic potential
- ♀ BSE/TSE free
- ♀ US patent-pending hydro-ethanolic extraction process
- ♀ GMO-free
- ♀ Manufactured in WHO- GMP, ISO 9001:2015, ISO 22000:2005, FSSC:22000, KOSHER, HALAL, NSF-US GMP, ZED-Gold certified facility

**Disclaimer** - Information provided is for healthcare professionals only & is not for individual use. The statements made above have not been evaluated by FDA to diagnose, treat, cure or prevent diseases.